Latest filing published 28 Apr 2026 for Bicara Therapeutics Inc., €18k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David Raben: trading record in brief
David Raben discloses dealings in Bicara Therapeutics Inc. to SEC (Form 4). We count 17 filings; the first trade dates from 9 October 2025 and the latest from 27 April 2026.
The open-market record consists of 8 sales worth €989k, with no purchase. The rest of the record consists of 9 option exercises. So far in 2026, the count stands at no purchases and 4 sales.
On 28 April 2026 came the latest disclosure, an option exercise for €18k in Bicara Therapeutics Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to David Raben
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,500 shares@ US$3.789814.2% of flowCommon StockSEC:0001628280-26-028054:0
- 5,500 shares@ US$22.878285.8% of flowCommon StockSEC:0001628280-26-028054:1
- 5,500 shares@ US$3.789812.5% of flowCommon StockSEC:0001628280-26-021543:0
- 5,500 shares@ US$3.7898Common StockSEC:0002034679-25-000006:0
- 22,000 shares@ US$3.789833.5% of flowCommon StockSEC:0002034679-25-000003:0
5 of 5 declarations
